3æ5 ã¨ããªãã¡ã¤ãå ¨ç±³ã§å£²ä¸No1ã®è¬å¤ã«ãªã£ã ã«ãã´ãª:åç²¾ç¥è¬ã¨ããªãã¡ã¤ ä»åã¯2013年度ã®ã¢ã¡ãªã«ã§ã®è¬å¤ã®å£²ä¸ãã¹ãï¼ï¼ï¼ã«ã¤ãã¦ã§ãããªãã¨ããã®ã¨ããªãã¡ã¤ãå ¨ã¦ã®è¬å¤ã®ä¸ã§å£²ãä¸ãNo1ã«è¼ããã®ã§ããã¢ã¡ãªã«äººã¯ã¨ããªãã¡ã¤ã飲ã¿ãªããã¹ãã¬ã¹ç¤¾ä¼ã§éããçãæãã¦ããã®ã§ãããhttp://www.medscape.com/viewarticle/813571#1ï¼Source: IMS National Sales Perspectives, IMS Healthï¼ ä»¥ä¸ã®è¬å¤ã2013年度ã®ã¢ã¡ãªã«åè¡å½ã§ã®å£²ä¸ãã¹ãï¼ï¼ã®è¬å¤ã§ãï¼2012å¹´10æ1æ¥ï½2013å¹´9æ30æ¥ï¼ã 1ãAbilifyã$6,460,215,3942ãNexiumã$6,135,667,6143ãHumiraã$5,549,996,8554ãCrestorã$5,310,818

{{#tags}}- {{label}}
{{/tags}}